Real-World Perspectives on the Role of TYK2 Inhibitors in the Treatment of Psoriasis
| Overview / Abstract: |
How are TYK2 inhibitors different from conventional JAK inhibitors? In what patient population would they be best suited? Find out in this expert-led clinical review and panel discussion that provides the knowledge you need on the investigational TYK2 inhibitors and their potential roles in personalized psoriasis treatment plans. This content is available across two modules, allowing you to choose where to focus your time. Discussion topics include: |
|
Expiration |
Sep 30, 2022 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
1.00 AMA PRA Category 1 Credit™ |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
April Armstrong, MD, MPH; Neal Bhatia, MD; Mark Lebwohl, MD |
|
Activity Specialities / Related Topics |
Dermatology, Family Medicine, Primary Care |
|
Sponsors / Supporters / Grant Providers |
This activity is supported by an educational grant from Bristol-Myers Squibb. |
|
Keywords / Search Terms |
ACHL CME, CE, April Armstrong, Mark Lebwohl, Neal Bhatia, Psoriasis, TYK2 Inhibitor, TYK2, JAK, Plaque Psoriasis, psoriatic arthritis, cytokine, Deucravacitinib, POETYK, Apremilast, PASI 75, BMS, sPGA, PSSD Symptom Score, DLQI, mechanistic profile, safety, efficacy, routes of administration, emerging, refractory psoriasis, treatment strategy Free CE CME |
|